News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Scoop Review Of Books: Rushing For Gold

The first section focuses particularly on the Victorian connections – commercial, legal, mining and personal, including migration statistics. But for me the most interesting chapters were in the middle sections about the people of the goldfields. More>>

Comedy Festival Review: VOTE BATT

The political campaigning in the US over the last eight months or so has provided a stark insight into how far political candidates are willing to go. This background came into focus as “former comedian” – now politician – Tim Batt ushered people up into the front seats, passing out badges and taking photographs with his not entirely adoring public... More>>

HRH QEII's 90th: New Zealand Post Birthday Stamps Fit For A Queen

New Zealand Post is celebrating the Queen’s 90th birthday with a special series of stamps and a limited edition silver coin. The Queen was born on 21 April 1926. To mark her birthday, New Zealand Post has produced ‘lenticular’ or moving stamps that feature nine different images of the Queen on just three stamps. More>>

ALSO:

Anzac Day: A Time To Stand Against Hatred

The Human Rights Commission says ANZAC Day is a time for New Zealanders to remember those things our grandparents stood for and stand up against intolerance and prejudice. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news